Premium
Erasca Inc (ERAS)
NASDAQ
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage progr... Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.11 | -6.58682634731 | 1.67 | 1.7192 | 1.51 | 1446130 | 1.6040801 | CS |
| 4 | -0.33 | -17.4603174603 | 1.89 | 2.11 | 1.51 | 1315856 | 1.76851925 | CS |
| 12 | -1.07 | -40.6844106464 | 2.63 | 3.3 | 1.51 | 1353148 | 2.33320907 | CS |
| 26 | -1.03 | -39.7683397683 | 2.59 | 3.305 | 1.51 | 1645742 | 2.64446554 | CS |
| 52 | -0.16 | -9.3023255814 | 1.72 | 3.45 | 1.51 | 1670696 | 2.54249234 | CS |
| 156 | -10.78 | -87.358184765 | 12.34 | 12.8 | 1.51 | 1073321 | 3.51271273 | CS |
| 260 | -14.34 | -90.1886792453 | 15.9 | 24.47 | 1.51 | 978820 | 4.56367214 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
